Invicta Diagnos. — 360° view

Invicta Diagnos, a company in the Healthcare Service Provider industry, reported revenue of ₹24 crore and net profit of ₹2.33 crore for the September 2026 quarter.

Invicta Diagnos. (NSE: INVICTA-SM) closed at ₹74.75 on 20 Nov 2026. Its market capitalisation is ₹94 crore and it trades at 21.1 times earnings.

Share price
₹74.75 (20 Nov 2026)
Market cap
₹94 Cr (20 Nov 2026)
P/E
21.07 (20 Nov 2026)
Revenue
₹24 Cr (September 2026 quarter)
Net profit
₹2 Cr (September 2026 quarter)
ROCE
19.4% (FY26)
ROE
14.0% (FY26)
Book value
₹45.8 (FY26)
Dividend yield
0.00% (last 12 months to 20 Nov 2026)
52-week high / low
₹83.00 / ₹60.00 (20 Nov 2026)
Sector
Healthcare
Industry
Healthcare Service Provider
Symbol
NSE: INVICTA-SM

Incorporated in January 2021, Invicta Diagnostic Limited offers radiology and pathology solutions

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.